Sheet 1 of 2

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use Set al sheets If necessary)

MAR 2 2 2004

ATTY. DOCKET NO. D0299 NP APPLICATION NO. 10/645,190 APPLICANT WANG ET AL. FILING DATE AUGUST 21, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER	\cong									
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE			
	AA									
	AB				-					
	AC,									
	AD									
	AE	•								
•	AF									
	AG									
	АН									
	Al									
	AJ									
	AK									
	AL									

FOREIGN PATENT DOCUMENTS

•		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM							
	AN		-					
	AO							
	AP							
	AQ		•					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

SM	AR	Alessandrini, A. et al., "MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia", Proc. Nat'l. Acad. Sci., USA, Vol. 96, No. 22, pp. 12866-12869 (1999)
SM	AS	Barone, F.C. et al., "SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia", The Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 2, pp. 312-321 (2001)
SM	АТ	Cano, E. et al., "Parallel signal processing among mammalian MAPKs", Trends Biochem. Sci., Vol. 20, pp. 117-122 (1995)

EXAMINER

/Sean Mcgarry/

DATE CONSIDERED

06/28/2006

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0299 NP APPLICATION NO. 10/645,190 APPLICANT WANG ET AL. FILING DATE AUGUST 21, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		(motoding Addio), Trac, Dato, Columnia pages, Ed.,					
SM	2AA	Huang, CK. et al., "LSP1 Is the Major Substrate for Mitogen-activated Protein Kinase-activated Protein Kinase 2 in Human Neutrophils", The Journal of Biological Chemistry, Vol. 272, No. 1, pp. 17-19 (1997)					
SM	2AB	Irving, E.A. et al., "Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat", Molecular Brain Research, Vol. 77, pp. 65-75 (2000)					
SM	2AC	Kotlyarov, A. et al., "MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis", Nature Cell Biology, Vol. 1, pp. 94-97 (1999)					
SM	2AD	Rouse, J. et al., "A Novel Kinase Cascade Triggered by Stress and Heat Shock That Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, Vol. 78, pp. 1027-1037 (1994)					
SM.	2AE	Sugino, T. et al., "Activation of Mitogen-Activated Protein Kinases after Transient Forebrain Ischemia in Gerbil Hippocampus", The Journal of Neuroscience, Vol. 20, No. 12, pp. 4506-4514 (2000)					
SM	2AF	Thomas, G. et al., "Participation of a stress-activated protein kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells", Eur. J. Biochem., Vol. 247, pp. 1180-1189 (1997)					
SM	2AG	Wang, H. et al., "Differential Regulation of IL-1 β and TNF- α RNA Expression by MEK1 Inhibitor after Focal Cerebral Ischemia in Mice", Biochemical and Biophysical Research Communications, Vol. 286, pp. 869-874 (2001)					
SM	2AH	Wang, X. et al., "Role of Immune and Inflammatory Mediators in CNS Injury", Drug News Perspect, Vol. 13, No. 3, pp. 133-140 (2000)					
SM	2AI	Werz, O. et al., "Arachidonic Acid Promotes Phosphorylation of 5-Lipoxygenase at Ser-271 by MAPK-activated Protein Kinase 2 (MK2)", The Journal of Biological Chemistry, Vol. 277, No. 17, pp. 14793-14800 (2002)					
Zhang, R.L. et al., "A rat model of focal embolic cerebral ischemia", Brain Research, \ 83-92 (1997)							
	AK						
	AL						
	AM						
	AN						
EXAMINE	R	/Sean Mcgarry/ DATE CONSIDERED 06/28/2006					

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

The Reveral sheets if necessary)

ATTY. DOCKET NO. D0299 NP APPLICATION NO. 10/645,190 APPLICANT WANG ET AL. FILING DATE AUGUST 21, 2003

Group

& TRADE	ARRE		U.S. PAT	ENT DOCUMENTS				
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS SUBCLA	SS F	ILING DAT
	AA							
	AB							-
	AC							
	AD							
	AE			•				
	AF							
	AG							
	АН							
	Al							
	AJ			 				
	AK							
	AL			•				
			FOREIGN PA	ATENT DOCUMENTS	3		•	
		DOCUMENT NUMBER	UMENT NUMBER DATE OFFICE CLASS SUBCLA		SUBCLASS	TRANSLATI		
	AM							
	AN							
	AO							
	AP				•	×=.2.		
	AQ							
		OTHER DOCL	JMENTS (Inclu	ding Author, Title, Date, Pert	inent pages, E	tc.)	1	
				n Kinase-Activated Prote			Deficie	encv
~~	AR	Protects Brain from Iso Vol. 277, No. 46, page	hemic Injury in I	Mice. The Journal of Bio	ological Che	mistry, 15 No	vembe	r 2002
SM								
	AS							
	AS AT	·	**************************************					

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.